Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LinearDNA COVID-19 vaccine candidate
- Development stage
- Unknown
- Lead developer
- Applied DNA Sciences
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**LinearDNA COVID-19 vaccine candidate** is an investigational **veterinary DNA vaccine** developed by **Applied DNA Sciences** and **EvviVax** for prevention of **SARS-CoV-2 infection in companion and other susceptible animal species**, especially domestic cats. The product consists of **PCR-produced linear DNA amplicons encoding a SARS-CoV-2 spike protein variant** and is delivered by **intramuscular injection followed by electroporation** to drive host-cell uptake and expression of spike antigen, thereby inducing antiviral immune responses. The candidate has been described as a **lyophilized, room-temperature-stable nucleic acid vaccine** manufactured on Applied DNA's LinearDNA platform, with development aimed at veterinary use and potential USDA conditional licensure.
- Brand names
- LinearDNA COVID-19 vaccine candidate
- Other names
- linear DNA veterinary COVID-19 vaccineLinearDNA veterinary COVID-19 vaccinefeline LinearDNA COVID-19 vaccineLinearDNA SARS-CoV-2 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on LinearDNA COVID-19 vaccine candidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LinearDNA COVID-19 vaccine candidate.